Skip to content

Expanded safety and acceptability study of 6% cellulose sulphate

Expanded safety and acceptability study of 6% cellulose sulphate

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN20671128
Enrollment
180
Registered
2004-04-01
Start date
2001-12-01
Completion date
Unknown
Last updated
2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sexually transmitted infection (STI) prevention Urological and Genital Diseases Sexually transmitted infection

Interventions

1. Test groups using Cellulose Sulphate (CS) gel with or without concurrent intercourse 2. Control groups using K-Y jelly with or without concurrent intercourse Total

Sponsors

UNDP/UNFPA/WHO/World Bank - Special Programme of Research, Development and Research Training in Human Reproduction
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Healthy, sexually abstinent and sexually active women 2. Considered to be at low risk for human immunodeficiency virus (HIV) 3. Recruited from family planning clinics and local communities in Kampala (Uganda), Mumbai (India), and Sagamu (Nigeria) 4. Aged between 18 and 50 years 5. Had regular menstrual cycles, or were on injectable contraceptives and amenorrhoeic for at least 6 months 6. Were not at risk for pregnancy (because of tubal ligation, steroidal contraceptives, or abstinence) 7. Willing to adhere to the study protocol

Exclusion criteria

Exclusion criteria: 1. Known to have an allergy to any component of CS gel or K-Y Jelly or condoms (cohort II only) 2. Currently pregnant or within 2 months from last pregnancy outcome 3. Known to abuse drug or alcohol 4. Had evidence of an infection with Trichomonas vaginalis, Candidiasis or bacterial vaginosis which did not resolve with treatment or if they had gonorrhoea or a chlamydial infection 5. Had a history of herpes or condylomata within the past 6 months 6. Had non-iatrogenic abnormal colposcopy findings involving deep disruption of the genital epithelium at enrolment

Design outcomes

Primary

MeasureTime frame
The number of women who experienced any signs and/or symptoms of genital irritation as reported by volunteers at any time during follow-up or as determined by naked eye examination of the genitalia, on colposcopy or microbiologic tests.

Secondary

MeasureTime frame
Adverse events

Countries

India, Nigeria, Switzerland, Uganda

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026